Circulating magnesium status is associated with type 2 diabetes remission after Roux-en-Y gastric bypass surgery [Elektronisk resurs] a long-term cohort study
-
Haenni, Arvo (författare)
-
Nilsen, Inger (författare)
-
Uppsala universitet Medicinska och farmaceutiska vetenskapsområdet (utgivare)
-
Uppsala universitet Medicinska och farmaceutiska vetenskapsområdet (utgivare)
-
Uppsala universitet Humanistisk-samhällsvetenskapliga vetenskapsområdet (utgivare)
- Publicerad: 2021
- Engelska.
-
Ingår i: Surgery for Obesity and Related Diseases. - 1550-7289. ; 17:2, 299-307
-
Läs hela texten
-
Läs hela texten
-
Läs hela texten
Sammanfattning
Ämnesord
Stäng
- BACKGROUND: Low serum magnesium levels predict cardiovascular and all-cause mortality in patients with typ 2 diabetes. SETTING: Outpatient clinic of obesity and central hospital. OBJECTIVES: To assess long-term alterations in circulating magnesium status after Roux-en-Y gastric bypass (RYGB) surgery and associations with remission of type 2 diabetes (T2D). METHODS: Retrospective analysis of 5-year outcomes of plasma magnesium (p-Mg) and glucometabolic statuses in patients who underwent primary RYGB and who completed the annual follow-up program. Data were investigated from 84 patients without diabetes and 62 with T2D before RYGB, who showed either prolonged remission (n = 30), temporary remission (n = 16), or no remission (n = 16) after surgery. RESULTS: Body mass indexes before RYGB were similar in patients with and without T2D, irrespective of remission. The patients not achieving remission showed longer diabetes durations; higher circulating glucose levels; more intensive antidiabetic drug treatment, including insulin; and significantly lower p-Mg concentrations (.73 [±.08] mmol/L compared with .80-.82 [±.07] mmol/L, respectively; P < .01) than the groups showing remission or without diabetes before surgery. After RYGB, the p-Mg increased similarly, by 10-12% in the groups with T2D before surgery, irrespective of remission; however, the nonremission group did not reach the p-Mg levels registered in the other groups after follow-up. The nonremission group reached .82 (.09) mmol/L, compared with .87 (.06) and .88 (.08) mmol/L (P < .05), respectively, in patients with remission or without a history of diabetes. CONCLUSION: The p-Mg concentrations increased after RYGB, with similar increments irrespective of T2D remission; however, the nonremission group started from an inferior level and did not reach the p-Mg concentrations seen in the groups achieving remission or without a history of diabetes before surgery.
Ämnesord
- Medical and Health Sciences (hsv)
- Clinical Medicine (hsv)
- Endocrinology and Diabetes (hsv)
- Medicin och hälsovetenskap (hsv)
- Klinisk medicin (hsv)
- Endokrinologi och diabetes (hsv)
- Medical and Health Sciences (hsv)
- Clinical Medicine (hsv)
- Surgery (hsv)
- Medicin och hälsovetenskap (hsv)
- Klinisk medicin (hsv)
- Kirurgi (hsv)
- Medical and Health Sciences (hsv)
- Clinical Medicine (hsv)
- Gastroenterology and Hepatology (hsv)
- Medicin och hälsovetenskap (hsv)
- Klinisk medicin (hsv)
- Gastroenterologi (hsv)
Genre
- government publication (marcgt)
Indexterm och SAB-rubrik
- Diabetes
- Diabetes remission
- Gastric bypass
- Magnesium
- Obesity
Inställningar
Hjälp
Ingår i annan publikation. Gå till titeln
Surgery for Obesity and Related Diseases